Background: Evidence on local therapy for cutaneous leishmaniasis (CL) in the Amazon remains limited, particularly in areas where multiple Leishmania species other than Leishmania braziliensis are prevalent. Methodology:In this prospective, single-arm study, patients with localized CL were treated with a three-dose schedule intralesional meglumine antimoniate (IL-MA) at a referral center in Santarm, Par, Brazil.Follow-up and outcome assessment also involved the use of mHealth tools.Results: Between 2022 and 2024, 127 patients were enrolled.Treatment effectiveness at day 120 ranged from 69.3% (intention-to-treat) to 76.8% (perprotocol) after the initial regimen.Following an additional intralesional cycle, effectiveness increased to 85.6%.One serious adverse event required brief hospitalization.Conclusions: IL-MA demonstrated favorable safety and moderate-to-high effectiveness, supporting its use as a pragmatic therapeutic option for CL in the Amazon region.The integration of mHealth tools proved valuable for remote monitoring and minimizing loss to follow-up, offering a promising approach for patient management and the generation of real-world evidence in endemic settings.
Assy et al. (Sun,) studied this question.